1 |
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-S55.
DOI
|
2 |
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
DOI
|
3 |
Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
DOI
|
4 |
Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat 2011;18:892-896.
DOI
|
5 |
Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080-2086.
DOI
|
6 |
Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol 2013;19:82-86.
DOI
|
7 |
Wang M, Da Y, Cai H, Lu Y, Wu L, Jia J. Telbivudine myopathy in a patient with chronic hepatitis B. Int J Clin Pharm 2012;34:422-425.
DOI
|
8 |
Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-1105.
DOI
|
9 |
Ambang T, Tan JS, Ong S, Wong KT, Goh KJ. Clinicopathological features of telbivudine-associated myopathy. PLoS ONE 2016;11:e0162760.
DOI
|
10 |
Lo YL, See SJ, Tan CK. Continuous single motor unit electromyographic activity in adefovir associated myopathy. J Clin Neurosci. 2008;15:1073-1074.
DOI
|
11 |
Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605.
DOI
|
12 |
Yuan K, Guochun W, Huang Z, Lin B, Zhou H, Lu X. Entecavir-associated myopathy: a case report and literature review. Muscle Nerve 2014;49:610-614.
DOI
|
13 |
Masanes F, Barrientos A, Cebrian M, Pedrol E, Miro O, Casademont J, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998;159:226-228.
DOI
|